What is the effect of systemic anticancer treatment on cognitive function?

被引:71
作者
Minisini, A
Atalay, G
Bottomley, A
Puglisi, F
Piccart, M
Biganzoli, L
机构
[1] Inst Jules Bordet, Unit Chemotherapy, B-1000 Brussels, Belgium
[2] Univ Udine, Med Oncol Unit, I-33100 Udine, Italy
[3] Marmara Univ Hosp, Dept Med Oncol, Istanbul, Turkey
[4] Eortc Data Ctr, Qual Life Unit, Brussels, Belgium
关键词
D O I
10.1016/S1470-2045(04)01465-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Treatment regimens for solid tumours have been extensively investigated for their physical toxic effects, but far less is known about the potential impairment of cognitive function by anticancer treatment regimens. Here, we review published studies that examined cognitive function in adult patients receiving systemic therapy for solid tumours. Our review suggests that patients can experience cognitive changes related to their treatment. However, several studies had methodological limitations, such as use of a limited sample size, lack of baseline assessment, and lack of control for potential confounding factors. Better designed clinical trials are required so that the difficulties patients face in terms of reduced cognitive function as a result of anticancer treatment can be fully elucidated. These trials should have sufficient statistical power and, importantly, should also be prospective.
引用
收藏
页码:273 / 282
页数:10
相关论文
共 78 条
[1]   NEUROPSYCHIATRIC MANIFESTATIONS OF HUMAN-LEUKOCYTE INTERFERON THERAPY IN PATIENTS WITH CANCER [J].
ADAMS, F ;
QUESADA, JR ;
GUTTERMAN, JU .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (07) :938-941
[2]   Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma [J].
Ahles, TA ;
Saykin, AJ ;
Furstenberg, CT ;
Cole, B ;
Mott, LA ;
Skalla, K ;
Whedon, MB ;
Bivens, S ;
Mitchell, T ;
Greenberg, ER ;
Silberfarb, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :485-493
[3]   Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: A study by the cancer and leukemia group B [J].
Ahles, TA ;
Silberfarb, PM ;
Herndon, J ;
Maurer, LH ;
Kornblith, AB ;
Aisner, J ;
Perry, MC ;
Eaton, WL ;
Zacharski, LL ;
Green, MR ;
Holland, JC .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1954-1960
[4]   A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma [J].
Amato, R ;
Meyers, C ;
Ellerhorst, J ;
Finn, L ;
Kilbourn, R ;
Sella, A ;
Logothetis, C .
ANNALS OF ONCOLOGY, 1995, 6 (09) :911-914
[5]  
Baum M, 2002, LANCET, V359, P2131
[6]   Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma [J].
Bendell, JC ;
Domchek, SM ;
Burstein, HJ ;
Harris, L ;
Younger, J ;
Kuter, I ;
Bunnell, C ;
Rue, M ;
Gelman, R ;
Winer, E .
CANCER, 2003, 97 (12) :2972-2977
[7]  
Bender C M, 2000, Clin Nurs Res, V9, P352, DOI 10.1177/10547730022158537
[8]   Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, P ;
Homer, CJ ;
Johnson, MS ;
Klein, JD ;
Lieu, TA ;
Orleans, CT ;
Peipert, JF ;
Pender, NJ ;
Siu, AL ;
Teutsch, SM ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (10) :834-839
[9]  
Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.0.CO
[10]  
2-H